MedTrace Logo

Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

NCT03342573 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-02-24

No results posted yet for this study

Summary

The primary objective of this study is to assess the potential effectiveness of Cosentyx in the treatment of adult-onset Pityriasis Rubra Pilaris or PRP.

Conditions

  • PITYRIASIS RUBRA PILARIS

Interventions

DRUG

Cosentyx

Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.

Sponsors & Collaborators

Principal Investigators

  • Jason C Sluzevich · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2022-01-01
Completion
2022-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03342573 on ClinicalTrials.gov